

Blocklisting Six Monthly Return

Hong Kong, Shanghai, & Florham Park, NJ - Monday, December 29, 2025: HUTCHMED (China) Limited ("[HUTCHMED](#)" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:

- | | |
|---|---|
| 1. Name of applicant: | HUTCHMED (China) Limited |
| 2. Name of scheme: | Share Option Scheme conditionally adopted by HUTCHMED in 2015 ("2015 HUTCHMED Share Option Scheme") |
| 3. Period of return: | From June 29, 2025 to December 28, 2025 |
| 4. Balance under scheme from previous return: | 2015 HUTCHMED Share Option Scheme: 45,992,018 ordinary shares of US 0.1 each |
| 5. The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: | 2015 HUTCHMED Share Option Scheme: Nil |
| 6. Number of securities issued/allotted under scheme during period: | 2015 HUTCHMED Share Option Scheme: 216,150 |
| 7. Balance under scheme not yet issued/allotted at end of the period: | 2015 HUTCHMED Share Option Scheme: 45,775,868 ordinary shares of US 0.1 each |
| 8. Number and class of securities originally listed and the date of admission: | 25,198,880 ordinary shares of US 0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019) |
| 9. Total number of securities in issue at the end of the period: | 872,327,620 ordinary shares of US 0.1 each |
| Name of contact: | Weiguo Su / Johnny Cheng |
| Address of contact: | Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong |
| Telephone number of contact: | +852 2121 8200 |

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on [LinkedIn](#).

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com

Media Enquiries

FTI Consulting -

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

Ben Atwell / Tim Stamper

+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)

Brunswick - Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickarou.com

Panmure Liberum
Atholl Tweedie / Emma Earl / Rupert Dearden

Nominated Advisor and Joint Broker
+44 20 7886 2500

Cavendish
Geoff Nash / Nigel Birks

Joint Broker
+44 20 7220 0500

Deutsche Numis
Freddie Barnfield / Jeffrey Wong / Duncan Monteith

Joint Broker
+44 20 7260 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLREAXALAESSFFA